These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9203959)

  • 1. The serum resistance of malaria-infected erythrocytes.
    Kawamoto Y; Kojima K; Hitsumoto Y; Okada H; Holers VM; Miyama A
    Immunology; 1997 May; 91(1):7-12. PubMed ID: 9203959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor.
    Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC
    Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
    Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
    Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
    Miwa T; Zhou L; Hilliard B; Molina H; Song WC
    Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.
    Kim DD; Miwa T; Song WC
    J Immunol; 2006 Oct; 177(8):5558-66. PubMed ID: 17015743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
    Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythrocyte membrane-associated immunoglobulins during malaria infection of mice.
    Lustig HJ; Nussenzweig V; Nussenzweig RS
    J Immunol; 1977 Jul; 119(1):210-6. PubMed ID: 326956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
    Harris CL; Spiller OB; Morgan BP
    Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF.
    Li B; Sallee C; Dehoff M; Foley S; Molina H; Holers VM
    J Immunol; 1993 Oct; 151(8):4295-305. PubMed ID: 7691944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement-mediated defect in clearance and sequestration of sensitized, autologous erythrocytes in rodent malaria.
    Pappas MG; Nussenzweig RS; Nussenzweig V; Shear HL
    J Clin Invest; 1981 Jan; 67(1):183-92. PubMed ID: 7005263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different appearance of parasitized erythrocytes in blood between normal and toxoplasma-infected rats after infection of Plasmodium berghei.
    Omata Y; Nakabayashi T; Suzuki N
    Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):362-73. PubMed ID: 388945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity.
    Miwa T; Zhou L; Tudoran R; Lambris JD; Madaio MP; Nangaku M; Molina H; Song WC
    Mol Immunol; 2007 Jan; 44(1-3):139-46. PubMed ID: 16887189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemiluminescence response of peritoneal macrophages to parasitized erythrocytes and lysed erythrocytes from Plasmodium berghei-infected mice.
    Makimura S; Brinkmann V; Mossmann H; Fischer H
    Infect Immun; 1982 Aug; 37(2):800-4. PubMed ID: 6749686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack.
    Barata L; Miwa T; Sato S; Kim D; Mohammed I; Song WC
    J Immunol; 2013 Mar; 190(6):2886-95. PubMed ID: 23390291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg.
    Kim DD; Miwa T; Kimura Y; Schwendener RA; van Lookeren Campagne M; Song WC
    Blood; 2008 Aug; 112(4):1109-19. PubMed ID: 18524992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.
    Horta MF; Ramalho-Pinto FJ
    J Exp Med; 1991 Dec; 174(6):1399-406. PubMed ID: 1720809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
    Schreiber AD; Frank MM
    J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of mouse complement by different classes of mouse antibody.
    Klaus GG; Pepys MB; Kitajima K; Askonas BA
    Immunology; 1979 Dec; 38(4):687-95. PubMed ID: 521057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.